Nektar Therapeutics Faces Securities Lawsuit Over Failed Trial
Analysis based on 22 articles · First reported Mar 06, 2026 · Last updated Apr 20, 2026
The market is negatively impacted by the news of Nektar Therapeutics' failed drug trial and the subsequent securities class action lawsuit, leading to a significant drop in Nektar Therapeutics' stock price. This event highlights the risks associated with biotechnology investments and the importance of transparent reporting.
Faruqi & Faruqi, LLP, a national securities law firm, is investigating Nektar Therapeutics, Inc. and has filed a federal securities class action lawsuit against the company. The lawsuit alleges that Nektar Therapeutics made false and misleading statements regarding its Phase 2b REZOLVE-AA trial for rezpegaldesleukin. Specifically, the complaint states that enrollment in the trial did not follow applicable instructions and protocol standards, which likely had a significant negative impact on the trial's results. On December 16, 2025, Nektar Therapeutics announced that the trial failed to reach statistical significance, attributing it to the inclusion of ineligible patients. This news caused Nektar Therapeutics' stock price to fall by 7.77%. Faruqi & Faruqi, LLP is encouraging investors who suffered losses between February 26, 2025, and December 15, 2025, to contact them to discuss their legal options and to seek the role of lead plaintiff by the May 5, 2026 deadline.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard